{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent has been administered to and safety data collected from 4328 adults 50 years of age and older (Study 6) and 998 adults 18-49 years of age (Study 7). SAEs were collected for 6 months post vaccination via clinic visit or remote contact. Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document, with only minor differences in formatting and spacing due to OCR artifacts. The content is semantically equivalent: 'Flublok Quadrivalent has been administered to and safety data collected from 4328 adults 50 years of age and older (Study 6) and 998 adults 18-49 years of age (Study 7). SAEs were collected for 6 months post vaccination via clinic visit or remote contact. Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' All numbers, study identifiers, and the comparator vaccine (Fluarix Quadrivalent) match exactly.. The quote directly states that Flublok Quadrivalent was evaluated in Study 6, which enrolled subjects 50 years of age and older, and that these subjects were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the comparator, manufactured by GlaxoSmithKline). This explicitly confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "presence_explanation": "The quote appears on page 3 of the document, with only minor differences in formatting and spacing due to OCR artifacts. The content is semantically equivalent: 'Flublok Quadrivalent has been administered to and safety data collected from 4328 adults 50 years of age and older (Study 6) and 998 adults 18-49 years of age (Study 7). SAEs were collected for 6 months post vaccination via clinic visit or remote contact. Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' All numbers, study identifiers, and the comparator vaccine (Fluarix Quadrivalent) match exactly.",
      "support_explanation": "The quote directly states that Flublok Quadrivalent was evaluated in Study 6, which enrolled subjects 50 years of age and older, and that these subjects were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the comparator, manufactured by GlaxoSmithKline). This explicitly confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "original_relevance": "This quote explicitly states that Flublok Quadrivalent was evaluated in a clinical trial (Study 6) against Fluarix Quadrivalent, confirming that the pivotal trial compared these two vaccines."
    },
    {
      "id": 2,
      "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quadrivalent or a Comparator inactivated influenza vaccine (Fluarix Quadrivalent, manufactured by GlaxoSmithKline). The safety analysis population included 998 recipients of Flublok Quadrivalent and 332 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quadrivalent or a Comparator inactivated influenza vaccine (Fluarix Quadrivalent, manufactured by GlaxoSmithKline). The safety analysis population included 998 recipients of Flublok Quadrivalent and 332 Comparator vaccine recipients.' The wording and factual content match the quote to verify, including the study number, age group, randomization, comparator (Fluarix Quadrivalent), manufacturer, and subject numbers.. The quote directly supports the claim that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine). It explicitly states that subjects were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent, confirming a head-to-head comparison in a clinical trial.",
      "presence_explanation": "The quote appears on page 3 of the document: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quadrivalent or a Comparator inactivated influenza vaccine (Fluarix Quadrivalent, manufactured by GlaxoSmithKline). The safety analysis population included 998 recipients of Flublok Quadrivalent and 332 Comparator vaccine recipients.' The wording and factual content match the quote to verify, including the study number, age group, randomization, comparator (Fluarix Quadrivalent), manufacturer, and subject numbers.",
      "support_explanation": "The quote directly supports the claim that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine). It explicitly states that subjects were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent, confirming a head-to-head comparison in a clinical trial.",
      "original_relevance": "This quote further supports the claim by showing that in another age group (18-49 years), Flublok Quadrivalent was directly compared to Fluarix Quadrivalent in a randomized trial."
    },
    {
      "id": 3,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document, specifically in the section summarizing the results of Study 6. The text states: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quad rival ent in activated influenza vaccine, Fluarix Quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' This matches the quote in content, with only minor formatting and spacing differences due to OCR and extraction, but all facts, numbers, and technical content are preserved.. The quote explicitly states that the comparator in Study 6 was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The quote also references Study 6 and its clinical trial registration, confirming the context is the pivotal trial. No inference is required; the support is direct and explicit.",
      "presence_explanation": "The quote appears on page 4 of the document, specifically in the section summarizing the results of Study 6. The text states: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quad rival ent in activated influenza vaccine, Fluarix Quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' This matches the quote in content, with only minor formatting and spacing differences due to OCR and extraction, but all facts, numbers, and technical content are preserved.",
      "support_explanation": "The quote explicitly states that the comparator in Study 6 was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The quote also references Study 6 and its clinical trial registration, confirming the context is the pivotal trial. No inference is required; the support is direct and explicit.",
      "original_relevance": "This quote clarifies that the comparator in Study 6 was specifically Fluarix Quadrivalent, directly supporting the claim that Flublok Quadrivalent was evaluated against this standard-dose vaccine in the pivotal trial."
    },
    {
      "id": "comp_2",
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' The wording and factual content match the quote to verify, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent' due to OCR), but all numbers, vaccine names, and study design details are preserved.. The quote directly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the standard-dose comparator), and provides the number of recipients in each group. This explicitly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 3 of the document: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' The wording and factual content match the quote to verify, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent' due to OCR), but all numbers, vaccine names, and study design details are preserved.",
      "support_explanation": "The quote directly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the standard-dose comparator), and provides the number of recipients in each group. This explicitly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote directly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent, supporting the claim that these two vaccines were compared in the pivotal trial."
    }
  ],
  "verification_stats": {
    "total_verified": 4
  },
  "image_evidence": [
    {
      "image_filename": "figure_p4_det_3_007.png",
      "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
      "image_type": "Figure",
      "page_number": 4,
      "block_id": "det_3_007",
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "supports_claim": true,
      "explanation": "Table showing PCR-confirmed influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) for subjects receiving the study vaccine versus a comparator; footnotes indicate the comparator is the U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GSK. Evidence: Footnote stating Comparator = U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent. The image explicitly names Fluarix Quadrivalent as the comparator vaccine in the pivotal trial, which supports the claim.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "Table showing PCR-confirmed influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) for subjects receiving the study vaccine versus a comparator; footnotes indicate the comparator is the U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GSK.",
        "evidence_found": "Footnote stating Comparator = U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent.",
        "reasoning": "The image explicitly names Fluarix Quadrivalent as the comparator vaccine in the pivotal trial, which supports the claim.",
        "confidence_notes": null
      }
    },
    {
      "image_filename": "table_p4_mrg_det_3_015.png",
      "image_path": "FlublokPI/extracted/figures/table_p4_mrg_det_3_015.png",
      "image_type": "Table",
      "page_number": 4,
      "block_id": "mrg_det_3_015",
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "supports_claim": true,
      "explanation": "A table from a clinical document listing pivotal immunogenicity studies of Flublok quadrivalent, including study design details, vaccine formulations, and comparator vaccines. Evidence: The table lists Flublok (quadrivalent) and shows that the comparator vaccine in the pivotal trial was Fluarix (quadrivalent standard-dose vaccine). The table directly shows Flublok (quadrivalent) being evaluated against Fluarix (quadrivalent standard-dose vaccine), which supports the claim Note: Image text is small and somewhat blurred, but the comparator Fluarix QIV is legible.",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "A table from a clinical document listing pivotal immunogenicity studies of Flublok quadrivalent, including study design details, vaccine formulations, and comparator vaccines.",
        "evidence_found": "The table lists Flublok (quadrivalent) and shows that the comparator vaccine in the pivotal trial was Fluarix (quadrivalent standard-dose vaccine).",
        "reasoning": "The table directly shows Flublok (quadrivalent) being evaluated against Fluarix (quadrivalent standard-dose vaccine), which supports the claim",
        "confidence_notes": "Image text is small and somewhat blurred, but the comparator Fluarix QIV is legible."
      }
    }
  ]
}